These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19915963)

  • 1. The application of electrostatic dry powder deposition technology to coat drug-eluting stents.
    Nukala RK; Boyapally H; Slipper IJ; Mendham AP; Douroumis D
    Pharm Res; 2010 Jan; 27(1):72-81. PubMed ID: 19915963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings.
    Lockwood NA; Hergenrother RW; Patrick LM; Stucke SM; Steendam R; Pacheco E; Virmani R; Kolodgie FD; Hubbard B
    J Biomater Sci Polym Ed; 2010; 21(4):529-52. PubMed ID: 20233507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Promising Approach for Improving the Coating Stability and In Vivo Performance of Biodegradable Polymer-Coated Sirolimus-Eluting Stent.
    Bedair TM; Kang SN; Joung YK; Han DK
    J Biomed Nanotechnol; 2016 Nov; 12(11):2015-28. PubMed ID: 29364616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation.
    Chitkara K; Hogrefe K; Vasa-Nicotera M; Swanson N; Gershlick AH
    J Invasive Cardiol; 2006 Sep; 18(9):417-22. PubMed ID: 16954580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a biodegradable sirolimus-eluting stent coated by ultrasonic atomizing spray.
    Kim SJ; Park JG; Kim JH; Heo JS; Choi JW; Jang YS; Yoon J; Lee SJ; Kwon IK
    J Nanosci Nanotechnol; 2011 Jul; 11(7):5689-97. PubMed ID: 22121592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
    Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
    Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying a novel electrostatic dry powder coating technology to pellets.
    Yang Q; Ma Y; Zhu J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):118-24. PubMed ID: 26478275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model.
    Otsuka F; Cheng Q; Yahagi K; Acampado E; Sheehy A; Yazdani SK; Sakakura K; Euller K; Perkins LEL; Kolodgie FD; Virmani R; Joner M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1248-1260. PubMed ID: 26292590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
    Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries.
    Sperling C; Waliszewski MW; Kherad B; Krackhardt F
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719826335. PubMed ID: 30803407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Koppara T; Joner M; Bayer G; Steigerwald K; Diener T; Wittchow E
    Thromb Haemost; 2012 Jun; 107(6):1161-71. PubMed ID: 22535188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The characteristics and in vivo suppression of neointimal formation with sirolimus-eluting polymeric stents.
    Chen MC; Chang Y; Liu CT; Lai WY; Peng SF; Hung YW; Tsai HW; Sung HW
    Biomaterials; 2009 Jan; 30(1):79-88. PubMed ID: 18838155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial.
    Ellert J; Maeng M; Raungaard B; Hansen KN; Kahlert J; Jensen SE; Bøtker HE; Hansen HS; Lassen JF; Christiansen EH; Jensen LO
    Coron Artery Dis; 2020 Sep; 31(6):485-492. PubMed ID: 32271243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of factors affecting electrostatic charging of pharmaceuticals and adhesive mixtures for inhalation.
    Kaialy W
    Int J Pharm; 2016 Apr; 503(1-2):262-76. PubMed ID: 26836710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained release coating of tablets with Eudragit(®) RS/RL using a novel electrostatic dry powder coating process.
    Qiao M; Luo Y; Zhang L; Ma Y; Stephenson TS; Zhu J
    Int J Pharm; 2010 Oct; 399(1-2):37-43. PubMed ID: 20678560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
    Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
    Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.